Aetna Expands Coverage for Sight Sciences' Glaucoma Devices
Event summary
- Aetna updated its Glaucoma Surgery Policy to recognize OMNI and SION as medically necessary for mild-to-moderate open-angle glaucoma.
- Coverage is retroactive to July 14, 2026, affecting approximately 25 million commercial covered lives.
- Sight Sciences now has broad payer access for its MIGS technologies across all major national payers.
- Aetna’s decision follows a rigorous clinical review process.
The big picture
Aetna’s decision to cover Sight Sciences’ OMNI and SION devices underscores a shift toward minimally invasive glaucoma surgery (MIGS) as a standard treatment option. This move aligns with broader industry trends favoring less invasive, more effective interventions for chronic eye diseases. With coverage now established across major payers, Sight Sciences is positioned to capture a larger share of the $9 billion global glaucoma market.
What we're watching
- Market Penetration
- How the expanded coverage will accelerate adoption of OMNI and SION among glaucoma patients.
- Reimbursement Dynamics
- Whether other major payers will follow Aetna’s lead in recognizing these technologies as medically necessary.
- Clinical Validation
- The pace at which clinical evidence supports the long-term efficacy of Sight Sciences' MIGS procedures.